Zhen Liu

Zhen Liu

Auto-generated profile, based on publicly available information

Zhen Liu

Department of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong Special Administrative Region 999077, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YWYuan Wang
Yuan Wang
JQJin Qu
Jin Qu
CXChuxiao Xiong
Chuxiao Xiong
BCBing Chen
Bing Chen
KXKai Xie
Kai Xie
Peng SHIPeng SHI
Peng SHI
Despite the tremendous clinical potential of nucleic acid–based vaccines, their efficacy to induce therapeutic immune response has been limited by the lack of efficient local gene delivery techniques in the human body. In this study, we develop a hydrogel-based organic electronic device (μEPO) for both transdermal delivery of nucleic acids and in vivo microarrayed cell electroporation, which is specifically oriented toward one-step transfection of DNAs in subcutaneous antigen-presenting cells (APCs) for cancer immunotherapy. The μEPO device contains an array of microneedle-shaped electrodes with pre-encapsulated dry DNAs. Upon a pressurized contact with skin tissue, the electrodes are rehydrated, electrically triggered to release DNAs, and then electroporate nearby cells, which can achieve in vivo transfection of more than 50% of the cells in the epidermal and upper dermal layer. As a proof-of-concept, the μEPO technique is employed to facilitate transdermal delivery of neoantigen genes to activate antigen-specific immune response for enhanced cancer immunotherapy based on a DNA vaccination strategy. In an ovalbumin (OVA) cancer vaccine model, we show that high-efficiency transdermal transfection of APCs with OVA-DNAs induces robust cellular and humoral immune responses, including antigen presentation and generation of IFN-γ + cytotoxic T lymphocytes with a more than 10-fold dose sparing over existing intramuscular injection (IM) approach, and effectively inhibits tumor growth in rodent animals.

22 May 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
ZLZhen Liu
Zhen Liu
XLXuan Luo
Xuan Luo
RYRichard Yan-Do
Richard Yan-Do
YWYuan Wang
Yuan Wang
XXXi Xie
Xi Xie
Peng SHIPeng SHI
Peng SHI